RE:RE:RE:Management says warrants are NOT being accelerated by the co
Valeo announced today that it has no intention at this time to accelerate the expiry of the share purchase warrants of the Company (the”Warrants”) issued pursuant to a short form prospectus dated July 11, 2019, each Warrant having an exercise price of $0.60 and an expiry date of July 25, 2022. All other terms of these Warrants remain unchanged, including the right of the Company to accelerate on occurrence of a subsequent acceleration event in accordance with the terms of the Warrants.
“Our summer product launches are leading to improved cash flow and we therefore will not accelerate the expiry date of the Warrants at this stage” said Steve Saviuk, President and CEO of Valeo Pharma.